Therapeutic targeting of lipid metabolism in cancer: Mechanisms, pathways, and translational prospects
Pathology - Research and Practice · 2026-07 · 283 · 156507
DOI: 10.1016/j.prp.2026.156507 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathology - Research and Practice, 2026-07. Verfasst von Nazmun Lyle und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Hi-Tech Medical College & Hospital-Rourkela, Rourkela, Odisha 769004, India. Electronic address: drlylehmchr@gmail.com. Hauptthemen laut MEDLINE: Neoplasms, Lipid Metabolism, Antineoplastic Agents. Die Arbeit nennt 145 Literaturangaben.
Abstract (Originalsprache)
Cancer cells undergo intense metabolic reprogramming to provide fast proliferation, persistence, immune evasion, and resistance to therapy. Malignant cells often rely on exogenous lipids and maintaining strict metabolic regulation. Cancer cells stimulate de novo lipogenesis, lipid uptake, and storage pathways even in nutrient-limited microenvironments. This review combines current knowledge of cancer types, highlights vital enzymatic regulators and translational prospects. A comprehensive literature review was conducted, focusing on the complex relationship between lipid metabolic pathways and oncogenesis. This review focuses on de novo fatty acid synthesis, lipid uptake mechanisms, and cholesterol regulation in cancer. Important therapeutic targets, including Acetyl-CoA carboxylase (ACC), ATP citrate lyase (ACLY), fatty acid synthase (FASN), and sterol regulatory element-binding proteins (SREBPs) were evaluated. It also emphasizes the role in resistance to chemotherapy, radiotherapy, and specific targeted therapies. Several studies have revealed that dysregulated lipid metabolism contributes to tumour growth, immune evasion, and treatment resistance. Evidence from preclinical and clinical studies revealed that treatments targeting small-molecule inhibitors of FASN, ACLY, SREBPs and CD36, show promising outcomes. Alterations in lipid metabolic pathways serve as critical nodes in oncogenic networks and immune modulation. The inclusion of dietetaey modifications and nanoparticle-conjugated drug delivery provides encouraging results against tumour development. This review combines the roles of key regulators, therapeutic targets, and biomarker approaches that can update future therapies. However, challenges persist, including drug-induced toxicity, metabolic changes, and tumour heterogeneity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, Hi-Tech Medical College & Hospital-Rourkela, Rourkela, Odisha 769004, India. Electronic address: drlylehmchr@gmail.com.
- Department of Pharmaceutical Technology, Maulana Abul Kalam Azad University of Technology, Nadia, West Bengal 741249, India. Electronic address: hossain.chowdhury@makautwb.ac.in.
- Department of Biotechnology & Medical Engineering, National Institute of Technology-Rourkela, Rourkela, Odisha 769008, India. Electronic address: kpr@nitrkl.ac.in.
Zitieren
APA
Lyle, N., Hossain, C. M., & Pramanik, K. (2026). Therapeutic targeting of lipid metabolism in cancer: Mechanisms, pathways, and translational prospects. Pathology - Research and Practice, 283, 156507. https://doi.org/10.1016/j.prp.2026.156507
Vancouver
Lyle N, Hossain CM, Pramanik K. Therapeutic targeting of lipid metabolism in cancer: Mechanisms, pathways, and translational prospects. Pathology - Research and Practice. 2026;283:156507. doi:10.1016/j.prp.2026.156507
BibTeX
@article{Lyle2026,
author = {Lyle, Nazmun and Hossain, Chowdhury Mobaswar and Pramanik, Krishna},
title = {Therapeutic targeting of lipid metabolism in cancer: Mechanisms, pathways, and translational prospects},
journal = {Pathology - Research and Practice},
year = {2026},
volume = {283},
pages = {156507},
doi = {10.1016/j.prp.2026.156507}
}
EUVIMED